The FDA has announced that it intends to evaluate changes to the regulatory framework governing Premarket Tobacco Product Applications, or PMTAs—including possible rulemaking to replace the current framework. 

For vape manufacturers, distributors, and retailers, the September 28 announcement opens an important discussion about the future of the federal review process. It does not immediately change product authorization requirements or establish a new pathway to market. 

 

What Did FDA Announce? 

In its official statement, FDA identified several reasons for reconsidering its approach: 

• Its experience implementing the 2021 PMTA rule. 

• Recent judicial developments, including a federal lawsuit challenging the framework. 

• The growth of an illicit and unregulated market. 

• The pace of new product introductions. 

FDA says it wants a modern framework that provides greater clarity and predictability while protecting public health. However, the announcement does not include proposed replacement language, specific changes to application requirements, or an implementation schedule.  

Why This Matters to Independent Vape Businesses 

For businesses trying to plan product development, purchasing, and long-term investment, regulatory predictability matters. 

Manufacturers need to understand what evidence an application must contain. Distributors need reliable information about the products they carry. Retailers need to make purchasing decisions without treating every regulatory announcement as an immediate change in what they can sell. 

A revised framework could help address those needs if it establishes clearer requirements and a workable review process. Whether it delivers those improvements will depend on the actual proposal and how FDA implements it. 

For independent companies, the central question is practical: will a revised system provide a realistic opportunity to demonstrate that their products meet the legal standard? 

That question deserves attention as the process develops. 

 

What Has Not Changed? 

FDA says it will continue processing PMTA submissions, reviewing products, and issuing regulatory decisions under existing statutory requirements. It also says the standard of appropriate for the protection of public health, commonly called APPH, will continue to apply.  

Businesses should therefore avoid interpreting the announcement as: 

• Authorization for a particular product. 

• Permission to launch a product without the required authorization. 

• A pause in the existing application process. 

• A guarantee that pending applications will receive favorable decisions. 

A possible replacement of FDA’s regulatory framework also should not be confused with repeal of the Tobacco Control Act. The agency’s announcement expressly says future changes will be undertaken consistent with applicable law. 

 

Does This Mean Flavored Vapes Will Be Authorized? 

The announcement does not promise new flavored vape authorizations. 

It does not identify flavors, brands, or product categories that would qualify under a revised framework. It also does not specify which scientific requirements might change. 

For companies developing flavored products, the questions to watch include: 

• Will FDA clarify the evidence needed to evaluate adult switching and youth initiation? 

• Will application requirements become more consistent and predictable? 

• How will any new rules apply to applications already under review? 

• Will independent manufacturers have a workable way to meet the requirements? 

These are issues businesses can raise as FDA develops its approach. They are not outcomes established by the September 28 statement. 

 

What Should Manufacturers, Wholesalers, and Retailers Do Now? 

Continue following the current process 

Manufacturers with pending applications should continue tracking FDA communications, deadlines, and requests for information. The announcement provides no basis for assuming those obligations have been suspended. 

Keep product claims accurate 

Sales teams should distinguish between a submitted application, a pending review, and an issued marketing authorization. A discussion of regulatory reform does not change a product’s individual status. 

Prepare examples of how the process affects your business 

Businesses can begin documenting specific problems: unclear evidence requirements, difficulty planning investment, uncertainty about pending applications, and the effects on suppliers, employees, and customers. 

Concrete examples will be more useful than general frustration when opportunities for public input arise. 

Watch for the next formal step 

FDA says future changes will include opportunities for public input. The announcement itself does not establish a comment deadline. Businesses should watch for a proposed rule, supporting documents, and instructions explaining how to participate.  

 

An Opening for Reform—With Details Still to Come 

FDA’s announcement puts possible replacement of the current PMTA framework on the table. For independent vape businesses, that creates an opportunity to advocate for clear scientific requirements, predictable reviews, and a process that companies can realistically navigate. 

The next test will be the substance of FDA’s proposal. 

Businesses need rules they can understand, evidence standards they can plan around, and decisions that allow them to make informed investments. Until FDA publishes more detail, the appropriate response is to stay engaged, keep current compliance obligations in view, and prepare to contribute to the public process. 

Source: FDA intends to evaluate changes to the PMTA regulatory framework — September 28, 2026